State Board of Administration of Florida Retirement System boosted its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 10.1% during the second quarter, Holdings Channel reports. The fund owned 7,813 shares of the company’s stock after buying an additional 715 shares during the period. State Board of Administration of Florida Retirement System owned 0.05% of Anika Therapeutics worth $419,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the company. Capstone Asset Management Co. boosted its stake in shares of Anika Therapeutics by 3.2% in the second quarter. Capstone Asset Management Co. now owns 4,830 shares of the company’s stock worth $259,000 after buying an additional 150 shares during the last quarter. Baltimore Washington Financial Advisors Inc. raised its position in Anika Therapeutics by 0.7% in the second quarter. Baltimore Washington Financial Advisors Inc. now owns 69,300 shares of the company’s stock valued at $3,717,000 after buying an additional 515 shares during the period. Barclays PLC raised its position in Anika Therapeutics by 1.8% in the first quarter. Barclays PLC now owns 40,218 shares of the company’s stock valued at $1,770,000 after buying an additional 718 shares during the period. Swiss National Bank raised its position in Anika Therapeutics by 4.3% in the second quarter. Swiss National Bank now owns 24,300 shares of the company’s stock valued at $1,304,000 after buying an additional 1,000 shares during the period. Finally, A.R.T. Advisors LLC raised its position in Anika Therapeutics by 5.1% in the first quarter. A.R.T. Advisors LLC now owns 22,858 shares of the company’s stock valued at $1,022,000 after buying an additional 1,100 shares during the period. Institutional investors and hedge funds own 77.84% of the company’s stock.
Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 1.32% during trading on Monday, reaching $48.28. The company had a trading volume of 14,928 shares. Anika Therapeutics Inc. has a 12 month low of $32.60 and a 12 month high of $54.96. The company has a market capitalization of $713.43 million, a P/E ratio of 21.07 and a beta of 1.49. The stock has a 50 day moving average of $47.67 and a 200-day moving average of $48.06.
Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The firm earned $26.60 million during the quarter, compared to the consensus estimate of $24.75 million. Anika Therapeutics had a return on equity of 17.24% and a net margin of 33.77%. The business’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.51 EPS. Equities research analysts expect that Anika Therapeutics Inc. will post $2.00 EPS for the current fiscal year.
Separately, Zacks Investment Research raised Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price target on the stock in a research report on Monday, August 1st.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.